(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that Dr. Sven Rohmann, CEO and Chairman of the Company, will be stepping down from his position as Chief Executive Officer of Helix BioPharma […]
(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that it has completed a licence agreement with the National Research Council of Canada (“NRC”) for the worldwide right to antiCEACAM6 […]
(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that Helix Immuno-Oncology (“HIO”) has signed a non-binding letter of intent with KEN Poland Limited Liability Partnership (“KEN POLAND”) in support of the European […]
(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, will be attending and/or presenting at the following conferences in the first half of 2017 in US. 20170213-Helix-PR.pdf
(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a clinical stage immunooncology company developing innovative drug candidates for the prevention and treatment of cancer, will be presenting on February 14, 2017 at the BIO CEO & Investor Conference, The Waldorf Astoria, New York, New York. 20170202-Helix-PR.pdf
(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that its poster entitled: CART cell harboring a camelid single domain antibody as a targeting agent to kill tumours expressing VEGFR2 […]
(Toronto, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced today the results of matters voted on at its annual and special meeting of shareholders held on January 17, 2017 (the “Meeting”). 20170117-Helix-PR2.pdf
(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has completed an additional closing of its previously announced private placement. On December 28, 2016, Helix issued 1,313,000 units under the private placement for […]
(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has received private placement subscription agreements for units totalling aggregate gross proceeds of approximately CAD1.82 million and had closed on CAD1.58 million. PR-12302016.pdf
(Toronto, Ontario) – Helix BioPharma Corp. (“Helix” or the “Company”) (TSX, FSE: “HBP”), a clinical stage, immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces today it has signed an exclusive out-license agreement with Xisle Pharma Ventures Trust (“Xisle”) for the Company’s late-stage, Biphasix™ technology platform, including the lead product […]